Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up

• Published in: ESMO open Vol. 7; no. 1; p. 100359
• Main Authors: Lasagna, A., Lilleri, D., Agustoni, F., Percivalle, E., Borgetto, S., Alessio, N., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J.C., Ferrari, A., Zavaglio, F., Arena, F., Secondino, S., Falzoni, M., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.02.2022; Elsevier
• Subjects: B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; BNT162 Vaccine - administration & dosage; BNT162 Vaccine - immunology; BNT162b2 anti-SARS-CoV-2 vaccine; cancer; COVID-19 - immunology; COVID-19 - prevention & control; Follow-Up Studies; Humans; Immune Checkpoint Inhibitors - administration & dosage; Immune Checkpoint Inhibitors - immunology; Immunity, Cellular - drug effects; Immunity, Humoral - drug effects; Leukocytes, Mononuclear - drug effects; Leukocytes, Mononuclear - immunology; Neoplasms - drug therapy; Neoplasms - immunology; neutralizing antibody; Original Research; PD-1/PD-L1 inhibitors; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; SARS-CoV-2 - immunology; spike-specific T-cell response; third dose; neutralizing antibody; BNT162b2 anti-SARS-CoV-2 vaccine; spike-specific T-cell response; cancer; PD-1/PD-L1 inhibitors; third dose

The durability of immunogenicity of SARS-CoV-2 vaccination in cancer patients remains to be elucidated. We prospectively evaluated the immunogenicity of the vaccine in triggering both the humoral and the cell-mediated immune response in cancer patients treated with anti-programmed cell death protein...